1. Home
  2. AVB vs RMD Comparison

AVB vs RMD Comparison

Compare AVB & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AVB

AvalonBay Communities Inc.

HOLD

Current Price

$184.06

Market Cap

25.7B

Sector

Real Estate

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$224.46

Market Cap

28.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVB
RMD
Founded
1978
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.7B
28.4B
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
AVB
RMD
Price
$184.06
$224.46
Analyst Decision
Hold
Buy
Analyst Count
15
10
Target Price
$198.40
$292.56
AVG Volume (30 Days)
690.5K
1.4M
Earning Date
04-27-2026
04-30-2026
Dividend Yield
3.86%
1.13%
EPS Growth
N/A
9.67
EPS
3.43
10.43
Revenue
$3,040,725,000.00
$2,957,013,000.00
Revenue This Year
$4.04
$10.60
Revenue Next Year
$5.03
$7.41
P/E Ratio
$53.66
$29.10
Revenue Growth
4.36
13.44
52 Week Low
$160.10
$180.27
52 Week High
$198.63
$293.81

Technical Indicators

Market Signals
Indicator
AVB
RMD
Relative Strength Index (RSI) 45.36 61.36
Support Level $173.71 $218.39
Resistance Level $186.62 $233.75
Average True Range (ATR) 3.59 7.14
MACD -0.72 1.23
Stochastic Oscillator 37.19 85.77

Price Performance

Historical Comparison
AVB
RMD

About AVB AvalonBay Communities Inc.

AvalonBay Communities owns a portfolio of 296 apartment communities with more than 90,000 units and is developing 24 additional properties with approximately 8,600 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

Share on Social Networks: